PortalPublikationenClinical validity of circulating tumour cells in patients wi...

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data

Standard

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data. / Bidard, François-Clément; Peeters, Dieter J; Fehm, Tanja; Nolé, Franco; Gisbert-Criado, Rafael; Mavroudis, Dimitrios; Grisanti, Salvatore; Generali, Daniele; Garcia-Saenz, Jose A; Stebbing, Justin; Caldas, Carlos; Gazzaniga, Paola; Manso, Luis; Zamarchi, Rita; de Lascoiti, Angela Fernandez; De Mattos-Arruda, Leticia; Ignatiadis, Michail; Lebofsky, Ronald; van Laere, Steven J; Meier-Stiegen, Franziska; Sandri, Maria-Teresa; Vidal-Martinez, Jose; Politaki, Eleni; Consoli, Francesca; Bottini, Alberto; Diaz-Rubio, Eduardo; Krell, Jonathan; Dawson, Sarah-Jane; Raimondi, Cristina; Rutten, Annemie; Janni, Wolfgang; Munzone, Elisabetta; Carañana, Vicente; Agelaki, Sofia; Almici, Camillo; Dirix, Luc; Solomayer, Erich-Franz; Zorzino, Laura; Johannes, Helene; Reis-Filho, Jorge S; Pantel, Klaus; Pierga, Jean-Yves; Michiels, Stefan.

in: LANCET ONCOL, Jahrgang 15, Nr. 4, 01.04.2014, S. 406-414.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bidard, F-C, Peeters, DJ, Fehm, T, Nolé, F, Gisbert-Criado, R, Mavroudis, D, Grisanti, S, Generali, D, Garcia-Saenz, JA, Stebbing, J, Caldas, C, Gazzaniga, P, Manso, L, Zamarchi, R, de Lascoiti, AF, De Mattos-Arruda, L, Ignatiadis, M, Lebofsky, R, van Laere, SJ, Meier-Stiegen, F, Sandri, M-T, Vidal-Martinez, J, Politaki, E, Consoli, F, Bottini, A, Diaz-Rubio, E, Krell, J, Dawson, S-J, Raimondi, C, Rutten, A, Janni, W, Munzone, E, Carañana, V, Agelaki, S, Almici, C, Dirix, L, Solomayer, E-F, Zorzino, L, Johannes, H, Reis-Filho, JS, Pantel, K, Pierga, J-Y & Michiels, S 2014, 'Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data', LANCET ONCOL, Jg. 15, Nr. 4, S. 406-414. https://doi.org/10.1016/S1470-2045(14)70069-5

APA

Bidard, F-C., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A. F., De Mattos-Arruda, L., Ignatiadis, M., Lebofsky, R., van Laere, S. J., ... Michiels, S. (2014). Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data. LANCET ONCOL, 15(4), 406-414. https://doi.org/10.1016/S1470-2045(14)70069-5

Vancouver

Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data. LANCET ONCOL. 2014 Apr 1;15(4):406-414. https://doi.org/10.1016/S1470-2045(14)70069-5

Bibtex

@article{58149f00e5584794adb60cb68cdf478b,
title = "Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data",
abstract = "BACKGROUND: We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data.METHODS: We contacted 51 European centres and asked them to provide reported and unreported anonymised data for individual patients with metastatic breast cancer who participated in studies between January, 2003, and July, 2012. Eligible studies had participants starting a new line of therapy, data for progression-free survival or overall survival, or both, and CTC quantification by the CellSearch method at baseline (before start of new treatment). We used Cox regression models, stratified by study, to establish the association between CTC count and progression-free survival and overall survival. We used the landmark method to assess the prognostic value of CTC and serum marker changes during treatment. We assessed the added value of CTCs or serum markers to prognostic clinicopathological models in a resampling procedure using likelihood ratio (LR) χ(2) statistics.FINDINGS: 17 centres provided data for 1944 eligible patients from 20 studies. 911 patients (46·9%) had a CTC count of 5 per 7·5 mL or higher at baseline, which was associated with decreased progression-free survival (hazard ratio [HR] 1·92, 95% CI 1·73-2·14, p<0·0001) and overall survival (HR 2·78, 95% CI 2·42-3·19, p<0·0001) compared with patients with a CTC count of less than 5 per 7·5 mL at baseline. Increased CTC counts 3-5 weeks after start of treatment, adjusted for CTC count at baseline, were associated with shortened progression-free survival (HR 1·85, 95% CI 1·48-2·32, p<0·0001) and overall survival (HR 2·26, 95% CI 1·68-3·03) as were increased CTC counts after 6-8 weeks (progression-free survival HR 2·20, 95% CI 1·66-2·90, p<0·0001; overall survival HR 2·91, 95% CI 2·01-4·23, p<0·0001). Survival prediction was significantly improved by addition of baseline CTC count to the clinicopathological models (progression-free survival LR 38·4, 95% CI 21·9-60·3, p<0·0001; overall survival LR 64·9, 95% CI 41·3-93·4, p<0·0001). This model was further improved by addition of CTC change at 3-5 weeks (progression-free survival LR 8·2, 95% CI 0·78-20·4, p=0·004; overall survival LR 11·5, 95% CI 2·6-25·1, p=0·0007) and at 6-8 weeks (progression-free survival LR 15·3, 95% CI 5·2-28·3; overall survival LR 14·6, 95% CI 4·0-30·6; both p<0·0001). Carcinoembryonic antigen and cancer antigen 15-3 concentrations at baseline and during therapy did not add significant information to the best baseline model.INTERPRETATION: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival. CTC count also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.FUNDING: Janssen Diagnostics, the Nuovo-Soldati foundation for cancer research.",
keywords = "Aged, Breast Neoplasms, Carcinoembryonic Antigen, Cell Count, Chi-Square Distribution, Disease-Free Survival, Europe, Female, Humans, Kaplan-Meier Estimate, Likelihood Functions, Middle Aged, Mucin-1, Neoplastic Cells, Circulating, Predictive Value of Tests, Proportional Hazards Models, Reproducibility of Results, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Tumor Markers, Biological",
author = "Fran{\c c}ois-Cl{\'e}ment Bidard and Peeters, {Dieter J} and Tanja Fehm and Franco Nol{\'e} and Rafael Gisbert-Criado and Dimitrios Mavroudis and Salvatore Grisanti and Daniele Generali and Garcia-Saenz, {Jose A} and Justin Stebbing and Carlos Caldas and Paola Gazzaniga and Luis Manso and Rita Zamarchi and {de Lascoiti}, {Angela Fernandez} and {De Mattos-Arruda}, Leticia and Michail Ignatiadis and Ronald Lebofsky and {van Laere}, {Steven J} and Franziska Meier-Stiegen and Maria-Teresa Sandri and Jose Vidal-Martinez and Eleni Politaki and Francesca Consoli and Alberto Bottini and Eduardo Diaz-Rubio and Jonathan Krell and Sarah-Jane Dawson and Cristina Raimondi and Annemie Rutten and Wolfgang Janni and Elisabetta Munzone and Vicente Cara{\~n}ana and Sofia Agelaki and Camillo Almici and Luc Dirix and Erich-Franz Solomayer and Laura Zorzino and Helene Johannes and Reis-Filho, {Jorge S} and Klaus Pantel and Jean-Yves Pierga and Stefan Michiels",
note = "Copyright {\textcopyright} 2014 Elsevier Ltd. All rights reserved.",
year = "2014",
month = apr,
day = "1",
doi = "10.1016/S1470-2045(14)70069-5",
language = "English",
volume = "15",
pages = "406--414",
journal = "LANCET ONCOL",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "4",

}

RIS

TY - JOUR

T1 - Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data

AU - Bidard, François-Clément

AU - Peeters, Dieter J

AU - Fehm, Tanja

AU - Nolé, Franco

AU - Gisbert-Criado, Rafael

AU - Mavroudis, Dimitrios

AU - Grisanti, Salvatore

AU - Generali, Daniele

AU - Garcia-Saenz, Jose A

AU - Stebbing, Justin

AU - Caldas, Carlos

AU - Gazzaniga, Paola

AU - Manso, Luis

AU - Zamarchi, Rita

AU - de Lascoiti, Angela Fernandez

AU - De Mattos-Arruda, Leticia

AU - Ignatiadis, Michail

AU - Lebofsky, Ronald

AU - van Laere, Steven J

AU - Meier-Stiegen, Franziska

AU - Sandri, Maria-Teresa

AU - Vidal-Martinez, Jose

AU - Politaki, Eleni

AU - Consoli, Francesca

AU - Bottini, Alberto

AU - Diaz-Rubio, Eduardo

AU - Krell, Jonathan

AU - Dawson, Sarah-Jane

AU - Raimondi, Cristina

AU - Rutten, Annemie

AU - Janni, Wolfgang

AU - Munzone, Elisabetta

AU - Carañana, Vicente

AU - Agelaki, Sofia

AU - Almici, Camillo

AU - Dirix, Luc

AU - Solomayer, Erich-Franz

AU - Zorzino, Laura

AU - Johannes, Helene

AU - Reis-Filho, Jorge S

AU - Pantel, Klaus

AU - Pierga, Jean-Yves

AU - Michiels, Stefan

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - BACKGROUND: We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data.METHODS: We contacted 51 European centres and asked them to provide reported and unreported anonymised data for individual patients with metastatic breast cancer who participated in studies between January, 2003, and July, 2012. Eligible studies had participants starting a new line of therapy, data for progression-free survival or overall survival, or both, and CTC quantification by the CellSearch method at baseline (before start of new treatment). We used Cox regression models, stratified by study, to establish the association between CTC count and progression-free survival and overall survival. We used the landmark method to assess the prognostic value of CTC and serum marker changes during treatment. We assessed the added value of CTCs or serum markers to prognostic clinicopathological models in a resampling procedure using likelihood ratio (LR) χ(2) statistics.FINDINGS: 17 centres provided data for 1944 eligible patients from 20 studies. 911 patients (46·9%) had a CTC count of 5 per 7·5 mL or higher at baseline, which was associated with decreased progression-free survival (hazard ratio [HR] 1·92, 95% CI 1·73-2·14, p<0·0001) and overall survival (HR 2·78, 95% CI 2·42-3·19, p<0·0001) compared with patients with a CTC count of less than 5 per 7·5 mL at baseline. Increased CTC counts 3-5 weeks after start of treatment, adjusted for CTC count at baseline, were associated with shortened progression-free survival (HR 1·85, 95% CI 1·48-2·32, p<0·0001) and overall survival (HR 2·26, 95% CI 1·68-3·03) as were increased CTC counts after 6-8 weeks (progression-free survival HR 2·20, 95% CI 1·66-2·90, p<0·0001; overall survival HR 2·91, 95% CI 2·01-4·23, p<0·0001). Survival prediction was significantly improved by addition of baseline CTC count to the clinicopathological models (progression-free survival LR 38·4, 95% CI 21·9-60·3, p<0·0001; overall survival LR 64·9, 95% CI 41·3-93·4, p<0·0001). This model was further improved by addition of CTC change at 3-5 weeks (progression-free survival LR 8·2, 95% CI 0·78-20·4, p=0·004; overall survival LR 11·5, 95% CI 2·6-25·1, p=0·0007) and at 6-8 weeks (progression-free survival LR 15·3, 95% CI 5·2-28·3; overall survival LR 14·6, 95% CI 4·0-30·6; both p<0·0001). Carcinoembryonic antigen and cancer antigen 15-3 concentrations at baseline and during therapy did not add significant information to the best baseline model.INTERPRETATION: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival. CTC count also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.FUNDING: Janssen Diagnostics, the Nuovo-Soldati foundation for cancer research.

AB - BACKGROUND: We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data.METHODS: We contacted 51 European centres and asked them to provide reported and unreported anonymised data for individual patients with metastatic breast cancer who participated in studies between January, 2003, and July, 2012. Eligible studies had participants starting a new line of therapy, data for progression-free survival or overall survival, or both, and CTC quantification by the CellSearch method at baseline (before start of new treatment). We used Cox regression models, stratified by study, to establish the association between CTC count and progression-free survival and overall survival. We used the landmark method to assess the prognostic value of CTC and serum marker changes during treatment. We assessed the added value of CTCs or serum markers to prognostic clinicopathological models in a resampling procedure using likelihood ratio (LR) χ(2) statistics.FINDINGS: 17 centres provided data for 1944 eligible patients from 20 studies. 911 patients (46·9%) had a CTC count of 5 per 7·5 mL or higher at baseline, which was associated with decreased progression-free survival (hazard ratio [HR] 1·92, 95% CI 1·73-2·14, p<0·0001) and overall survival (HR 2·78, 95% CI 2·42-3·19, p<0·0001) compared with patients with a CTC count of less than 5 per 7·5 mL at baseline. Increased CTC counts 3-5 weeks after start of treatment, adjusted for CTC count at baseline, were associated with shortened progression-free survival (HR 1·85, 95% CI 1·48-2·32, p<0·0001) and overall survival (HR 2·26, 95% CI 1·68-3·03) as were increased CTC counts after 6-8 weeks (progression-free survival HR 2·20, 95% CI 1·66-2·90, p<0·0001; overall survival HR 2·91, 95% CI 2·01-4·23, p<0·0001). Survival prediction was significantly improved by addition of baseline CTC count to the clinicopathological models (progression-free survival LR 38·4, 95% CI 21·9-60·3, p<0·0001; overall survival LR 64·9, 95% CI 41·3-93·4, p<0·0001). This model was further improved by addition of CTC change at 3-5 weeks (progression-free survival LR 8·2, 95% CI 0·78-20·4, p=0·004; overall survival LR 11·5, 95% CI 2·6-25·1, p=0·0007) and at 6-8 weeks (progression-free survival LR 15·3, 95% CI 5·2-28·3; overall survival LR 14·6, 95% CI 4·0-30·6; both p<0·0001). Carcinoembryonic antigen and cancer antigen 15-3 concentrations at baseline and during therapy did not add significant information to the best baseline model.INTERPRETATION: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival. CTC count also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.FUNDING: Janssen Diagnostics, the Nuovo-Soldati foundation for cancer research.

KW - Aged

KW - Breast Neoplasms

KW - Carcinoembryonic Antigen

KW - Cell Count

KW - Chi-Square Distribution

KW - Disease-Free Survival

KW - Europe

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Likelihood Functions

KW - Middle Aged

KW - Mucin-1

KW - Neoplastic Cells, Circulating

KW - Predictive Value of Tests

KW - Proportional Hazards Models

KW - Reproducibility of Results

KW - Retrospective Studies

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Tumor Markers, Biological

U2 - 10.1016/S1470-2045(14)70069-5

DO - 10.1016/S1470-2045(14)70069-5

M3 - SCORING: Journal article

C2 - 24636208

VL - 15

SP - 406

EP - 414

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 4

ER -